As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside
Early Data Suggests Superiority Against Pain Crises
Executive Summary
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
You may also be interested in...
Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.